市場調査レポート
商品コード
1545635

遺伝子編集治療の世界市場

Gene Editing Therapeutics Market

出版日: | 発行: BCC Research | ページ情報: 英文 111 Pages | 納期: 即納可能 即納可能とは

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=154.02円
遺伝子編集治療の世界市場
出版日: 2024年08月30日
発行: BCC Research
ページ情報: 英文 111 Pages
納期: 即納可能 即納可能とは
  • 全表示
  • 概要
  • 図表
  • 目次
概要

当レポートでは、世界の遺伝子編集治療の市場を調査し、市場概要、市場影響因子および市場機会の分析、新興技術および技術開発の動向、パイプライン分析、市場規模の推移・予測、各種区分・地域別の詳細分析、競合情勢、主要企業のプロファイルなどをまとめています。

目次

第1章 エグゼクティブサマリー

  • 市場見通し
  • 調査範囲
  • 市場概要

第2章 市場概要

  • ゲノム編集ツールの種類
  • メガヌクレアーゼ
  • ジンクフィンガーヌクレアーゼ
  • 転写活性化因子様エフェクターヌクレアーゼ
  • CRISPR/CRISPR関連タンパク質 9
  • 遺伝子編集治療

第3章 市場力学

  • 市場力学スナップショット
  • 市場促進要因
  • 慢性疾患の蔓延
  • 希少遺伝性疾患の増加
  • 精密医療
  • 戦略的取り組みの強化
  • 市場抑制要因
  • 厳格な規制枠組みと時間のかかる承認プロセス
  • 治療費の高騰
  • 有害事象と長期モニタリング
  • 熟練技術者の不足
  • オフターゲットの影響
  • 市場の課題
  • 特許紛争
  • 政府の政策と規制
  • 倫理的問題
  • 市場機会

第4章 新興技術と開発

  • ベース編集
  • プライム編集
  • Cas-CloverとCas-FOKl
  • CRISPR干渉とCRISPR活性化
  • RNA編集
  • ゲノム編集におけるAI

第5章 パイプライン分析

  • 概要
  • 臨床試験分析:技術別
  • 臨床試験分析:疾患別
  • パイプライン薬の指定

第6章 特許分析

第7章 市場分析

  • Casgevy
  • 市場概要
  • 市場分析
  • 地域別市場
  • 北米
  • 欧州
  • 新興市場

第8章 競合情報

  • 戦略的取り組み
  • 競合情勢

第9章 遺伝子編集治療市場における持続可能性:環境・社会・ガバナンス(ESG)の観点

  • 遺伝子編集企業におけるESGの実践
  • BCCからの結論

第10章 付録

  • 調査手法
  • 出典
  • 頭字語
  • 企業プロファイル
  • ALLOGENE THERAPEUTICS
  • BEAM THERAPEUTICS
  • CARIBOU BIOSCIENCES INC.
  • CRISPR THERAPEUTICS
  • EDITAS MEDICINE
  • INTELLIA THERAPEUTICS INC.
  • PRECISION BIOSCIENCES
  • SANGAMO THERAPEUTICS
  • VERTEX PHARMACEUTICALS INC.
  • VERVE THERAPEUTICS INC.
  • VOR BIO
図表

List of Tables

  • Summary Table : Global Market for Gene Editing Therapeutics, Through 2029
  • Table 1 : Comparison of Genome-Editing Tools
  • Table 2 : U.S. Adults Age 50 Years and Older with Multiple Chronic Conditions, 2020-2050
  • Table 3 : Global Cases and Deaths Due to Various Cancers, 2022
  • Table 4 : Gene Editing Index Ratings, 2020
  • Table 5 : Rating Guide
  • Table 6 : Comparison of Cas9-derived Proteins with Regular SpCas9
  • Table 7 : Gene Editing Therapeutic Trials in Phase I, Till May 2024
  • Table 8 : Gene Editing Therapeutic Trials in Phase I/II, II and III, Till May 2024
  • Table 9 : Casgevy Label Expansion Studies, Till May 2024
  • Table 10 : Examples of Some Pipeline Drugs and Their Designations, as of May 2024
  • Table 11 : Patents on CRISPR Therapeutics, Published in 2021
  • Table 12 : Patents on CRISPR Therapeutics, Published in 2022
  • Table 13 : Patents on CRISPR Therapeutics, Published in 2023
  • Table 14 : Global Market for Gene Editing Therapeutics, Through 2029
  • Table 15 : Global Market for Gene Editing Therapeutics, by Region, Through 2029
  • Table 16 : Strategic Initiatives in the Gene Editing Therapeutics Market, 2020-2024
  • Table 17 : Venture Funding for Startups, 2023
  • Table 18 : ESG Initiatives/Practices by Various Gene Editing Companies, 2023
  • Table 19 : ESG Rankings for Companies in the Gene Editing Therapeutics Market, 2023
  • Table 20 : Report Information Sources
  • Table 21 : Glossary of Terms Used in This Report
  • Table 22 : Allogene Therapeutics: Company Snapshot
  • Table 23 : Allogene Therapeutics: Financial Performance, FY 2022 and 2023
  • Table 24 : Allogene Therapeutics: News/Key Developments, 2020-2024
  • Table 25 : Beam Therapeutics: Company Snapshot
  • Table 26 : Beam Therapeutics: Financial Performance, FY 2022 and 2023
  • Table 27 : Beam Therapeutics: News/Key Developments, 2021-2023
  • Table 28 : Caribou Biosciences Inc.: Company Snapshot
  • Table 29 : Caribou Biosciences Inc.: Financial Performance, FY 2022 and 2023
  • Table 30 : Caribou Biosciences Inc.: News/Key Developments, 2021-2024
  • Table 31 : CRISPR Therapeutics: Company Snapshot
  • Table 32 : CRISPR Therapeutics: Financial Performance, FY 2022 and 2023
  • Table 33 : CRISPR Therapeutics: Product Portfolio
  • Table 34 : CRISPR Therapeutics: News/Key Developments, 2021-2024
  • Table 35 : Editas Medicine: Company Snapshot
  • Table 36 : Editas Medicine: Financial Performance, FY 2022 and 2023
  • Table 37 : Editas Medicine: News/Key Developments, 2022-2024
  • Table 38 : Intellia Therapeutics Inc.: Company Snapshot
  • Table 39 : Intellia Therapeutics Inc.: Financial Performance, FY 2022 and 2023
  • Table 40 : Intellia Therapeutics Inc.: News/Key Developments, 2021-2024
  • Table 41 : Precision Biosciences: Company Snapshot
  • Table 42 : Precision Biosciences: Financial Performance, FY 2022 and 2023
  • Table 43 : Precision Biosciences: News/Key Developments, 2020-2024
  • Table 44 : Sangamo Therapeutics: Company Snapshot
  • Table 45 : Sangamo Therapeutics: Financial Performance, FY 2022 and 2023
  • Table 46 : Sangamo Therapeutics: News/Key Developments, 2024
  • Table 47 : Vertex Pharmaceuticals Inc.: Company Snapshot
  • Table 48 : Vertex Pharmaceuticals Inc.: Financial Performance, FY 2022 and 2023
  • Table 49 : Vertex Pharmaceuticals Inc.: Product Portfolio
  • Table 50 : Vertex Pharmaceuticals Inc.: News/Key Developments, 2023 and 2024
  • Table 51 : Verve Therapeutics Inc.: Company Snapshot
  • Table 52 : Verve Therapeutics Inc.: Financial Performance, FY 2022 and 2023
  • Table 53 : Verve Therapeutics Inc.: News/Key Developments, 2019-2024
  • Table 54 : Vor Bio: Company Snapshot
  • Table 55 : Vor Bio: Financial Performance, FY 2022 and 2023
  • Table 56 : Vor Bio: News/Key Developments, 2020-2024

List of Figures

  • Summary Figure : Global Market for Gene Editing Therapeutics, 2021-2029
  • Figure 1 : Genome-Editing Outcomes
  • Figure 2 : Endonucleases Used in Gene Editing Technologies
  • Figure 3 : Advances in Therapeutic Strategies to Treat Life-Threatening Diseases
  • Figure 4 : CRISPR/Cas9 Therapeutics Timeline, Since 1987-Present
  • Figure 5 : CRISPR/Cas9 Therapeutics Delivery Platform
  • Figure 6 : Delivery Method
  • Figure 7 : Market Dynamics of Gene Editing Therapeutics Market
  • Figure 8 : Genetic Disorders
  • Figure 9 : Emerging Technologies in the Genome-Editing Therapeutics Market
  • Figure 10 : Emerging Therapeutics Applications for RNA Editing by Cas Enzymes
  • Figure 11 : Articles on Gene Editing Therapeutics in PubMed, 2004-2024
  • Figure 12 : Share of Clinical Trials on the Genome-Editing Market, by Technology, Through May 2024
  • Figure 13 : Genome-Editing Clinical Trials, by Diseases
  • Figure 14 : Genome-Editing Clinical Trials, by Trial Phase
  • Figure 15 : Genome-Editing Clinical Trials, by Trial Status
  • Figure 16 : Patents Documented, by Top Owners, 2021-2024
  • Figure 17 : Patents Documented, by Type, 2021-2024
  • Figure 18 : Patents Documented, by Type, 2021-2024
  • Figure 19 : Common Strategies Proposed for the Therapeutic Intervention for B-thalassemia and Sickle Cell Disease
  • Figure 20 : Caribou Biosciences Inc.: Revenue Share, by Country/Region, FY 2023
  • Figure 21 : Vertex Pharmaceuticals Inc.: Revenue Share, by Business Unit, FY 2023
  • Figure 22 : Vertex Pharmaceuticals Inc.: Revenue Share, by Country/Region, FY 2023
目次
Product Code: BIO259A

The report provides an overview of current and future market potential of gene editing therapeutics and provides a detailed analysis of the drivers, restraints and opportunities in this market. It also include company profiles of key players, featuring detailed information regarding each company’s business segments, financials, product portfolios and recent developments. 

Report Scope:

This report highlights the current and future market potential of gene editing therapeutics and provides a detailed analysis of the drivers, restraints and opportunities in this market. It also surveys the competitive environment, including coverage of the pipeline activities adopted by market players, and it includes market projections for 2029. Also included are company profiles of key players, featuring detailed information regarding each company's business segments, financials, product portfolios and recent developments.

Report Includes:

  • 15 data tables and 42 additional tables
  • An analysis of the current and future global markets for gene editing therapeutics
  • Analyses of global market trends, with market revenue data (sales figures) for 2021-2023, estimates for 2024, and projected CAGRs through 2029
  • Estimates of the market size and revenue forecasts for the global gene editing therapeutics market, with market share analysis by region
  • Discussion of the market dynamics, opportunities, and challenges, as well as emerging technologies
  • Overview of sustainability trends and ESG developments in the industry, with emphasis on the ESG practices of leading companies, their ESG rankings, and consumer attitudes
  • Competitive intelligence, including companies' market shares, recent M&A activity, and venture funding
  • Company profiles of major players within the industry, including CRISPR Therapeutics, Vertex Pharmaceuticals, and Intellia Therapeutics

Table of Contents

Chapter 1 Executive Summary

  • Market Outlook
  • Scope of Report
  • Market Summary

Chapter 2 Market Overview

  • Introduction
  • Genome-Editing Tool Types
  • Meganucleases
  • Zinc Finger Nucleases
  • Transcription Activator-like Effector Nucleases
  • Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-Associated Protein 9
  • Gene editing Therapeutics

Chapter 3 Market Dynamics

  • Market Dynamics Snapshot
  • Market Drivers
  • Increasing Prevalence of Chronic Disease
  • Increasing Prevalence of Rare Genetic Disorders
  • Precision Medicine
  • Increasing Strategic Initiatives
  • Market Restraints
  • Stringent Regulatory Frameworks and Time-Consuming Approval Processes
  • High Cost of Treatment
  • Adverse Events and Long-Term Monitoring
  • Lack of Skilled Workforce
  • Off-Target Impact
  • Market Challenges
  • Patent Disputes
  • Governmental Policies and Regulations
  • Ethical Issues
  • Market Opportunities

Chapter 4 Emerging Technologies and Developments

  • Introduction
  • Base Editing
  • Prime Editing
  • Cas-Clover and Cas-FOKl
  • CRISPR Interference and CRISPR Activation
  • RNA Editing
  • Artificial Intelligence in Genome Editing

Chapter 5 Pipeline Analysis

  • Overview
  • Clinical Trial Analysis Based on Technology
  • Clinical Trial Analysis Based on Diseases
  • Designations for Pipeline Drugs

Chapter 6 Patent Analysis

Chapter 7 Market Analysis

  • Introduction
  • Casgevy
  • Market Overview
  • Market Analysis
  • Market by Region
  • North America
  • Europe
  • Emerging Markets

Chapter 8 Competitive Intelligence

  • Strategic Initiatives
  • Competitive Landscape

Chapter 9 Sustainability in the Gene Editing Therapeutics Market: Environmental, Social and Governance (ESG) Perspectives

  • Introduction
  • ESG Practices in the Gene Editing Companies
  • Concluding Remarks from BCC Research

Chapter 10 Appendix

  • Methodology
  • Sources
  • Acronyms
  • Company Profiles
  • ALLOGENE THERAPEUTICS
  • BEAM THERAPEUTICS
  • CARIBOU BIOSCIENCES INC.
  • CRISPR THERAPEUTICS
  • EDITAS MEDICINE
  • INTELLIA THERAPEUTICS INC.
  • PRECISION BIOSCIENCES
  • SANGAMO THERAPEUTICS
  • VERTEX PHARMACEUTICALS INC.
  • VERVE THERAPEUTICS INC.
  • VOR BIO